Cargando…

Mothers after Gestational Diabetes in Australia (MAGDA): A Randomised Controlled Trial of a Postnatal Diabetes Prevention Program

BACKGROUND: Gestational diabetes mellitus (GDM) is an increasingly prevalent risk factor for type 2 diabetes. We evaluated the effectiveness of a group-based lifestyle modification program in mothers with prior GDM within their first postnatal year. METHODS AND FINDINGS: In this study, 573 women wer...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Reilly, Sharleen L., Dunbar, James A., Versace, Vincent, Janus, Edward, Best, James D., Carter, Rob, Oats, Jeremy J. N., Skinner, Timothy, Ackland, Michael, Phillips, Paddy A., Ebeling, Peter R., Reynolds, John, Shih, Sophy T. F., Hagger, Virginia, Coates, Michael, Wildey, Carol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961439/
https://www.ncbi.nlm.nih.gov/pubmed/27459502
http://dx.doi.org/10.1371/journal.pmed.1002092
_version_ 1782444674064056320
author O’Reilly, Sharleen L.
Dunbar, James A.
Versace, Vincent
Janus, Edward
Best, James D.
Carter, Rob
Oats, Jeremy J. N.
Skinner, Timothy
Ackland, Michael
Phillips, Paddy A.
Ebeling, Peter R.
Reynolds, John
Shih, Sophy T. F.
Hagger, Virginia
Coates, Michael
Wildey, Carol
author_facet O’Reilly, Sharleen L.
Dunbar, James A.
Versace, Vincent
Janus, Edward
Best, James D.
Carter, Rob
Oats, Jeremy J. N.
Skinner, Timothy
Ackland, Michael
Phillips, Paddy A.
Ebeling, Peter R.
Reynolds, John
Shih, Sophy T. F.
Hagger, Virginia
Coates, Michael
Wildey, Carol
author_sort O’Reilly, Sharleen L.
collection PubMed
description BACKGROUND: Gestational diabetes mellitus (GDM) is an increasingly prevalent risk factor for type 2 diabetes. We evaluated the effectiveness of a group-based lifestyle modification program in mothers with prior GDM within their first postnatal year. METHODS AND FINDINGS: In this study, 573 women were randomised to either the intervention (n = 284) or usual care (n = 289). At baseline, 10% had impaired glucose tolerance and 2% impaired fasting glucose. The diabetes prevention intervention comprised one individual session, five group sessions, and two telephone sessions. Primary outcomes were changes in diabetes risk factors (weight, waist circumference, and fasting blood glucose), and secondary outcomes included achievement of lifestyle modification goals and changes in depression score and cardiovascular disease risk factors. The mean changes (intention-to-treat [ITT] analysis) over 12 mo were as follows: −0.23 kg body weight in intervention group (95% CI −0.89, 0.43) compared with +0.72 kg in usual care group (95% CI 0.09, 1.35) (change difference −0.95 kg, 95% CI −1.87, −0.04; group by treatment interaction p = 0.04); −2.24 cm waist measurement in intervention group (95% CI −3.01, −1.42) compared with −1.74 cm in usual care group (95% CI −2.52, −0.96) (change difference −0.50 cm, 95% CI −1.63, 0.63; group by treatment interaction p = 0.389); and +0.18 mmol/l fasting blood glucose in intervention group (95% CI 0.11, 0.24) compared with +0.22 mmol/l in usual care group (95% CI 0.16, 0.29) (change difference −0.05 mmol/l, 95% CI −0.14, 0.05; group by treatment interaction p = 0.331). Only 10% of women attended all sessions, 53% attended one individual and at least one group session, and 34% attended no sessions. Loss to follow-up was 27% and 21% for the intervention and control groups, respectively, primarily due to subsequent pregnancies. Study limitations include low exposure to the full intervention and glucose metabolism profiles being near normal at baseline. CONCLUSIONS: Although a 1-kg weight difference has the potential to be significant for reducing diabetes risk, the level of engagement during the first postnatal year was low. Further research is needed to improve engagement, including participant involvement in study design; it is potentially more effective to implement annual diabetes screening until women develop prediabetes before offering an intervention. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12610000338066
format Online
Article
Text
id pubmed-4961439
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-49614392016-08-08 Mothers after Gestational Diabetes in Australia (MAGDA): A Randomised Controlled Trial of a Postnatal Diabetes Prevention Program O’Reilly, Sharleen L. Dunbar, James A. Versace, Vincent Janus, Edward Best, James D. Carter, Rob Oats, Jeremy J. N. Skinner, Timothy Ackland, Michael Phillips, Paddy A. Ebeling, Peter R. Reynolds, John Shih, Sophy T. F. Hagger, Virginia Coates, Michael Wildey, Carol PLoS Med Research Article BACKGROUND: Gestational diabetes mellitus (GDM) is an increasingly prevalent risk factor for type 2 diabetes. We evaluated the effectiveness of a group-based lifestyle modification program in mothers with prior GDM within their first postnatal year. METHODS AND FINDINGS: In this study, 573 women were randomised to either the intervention (n = 284) or usual care (n = 289). At baseline, 10% had impaired glucose tolerance and 2% impaired fasting glucose. The diabetes prevention intervention comprised one individual session, five group sessions, and two telephone sessions. Primary outcomes were changes in diabetes risk factors (weight, waist circumference, and fasting blood glucose), and secondary outcomes included achievement of lifestyle modification goals and changes in depression score and cardiovascular disease risk factors. The mean changes (intention-to-treat [ITT] analysis) over 12 mo were as follows: −0.23 kg body weight in intervention group (95% CI −0.89, 0.43) compared with +0.72 kg in usual care group (95% CI 0.09, 1.35) (change difference −0.95 kg, 95% CI −1.87, −0.04; group by treatment interaction p = 0.04); −2.24 cm waist measurement in intervention group (95% CI −3.01, −1.42) compared with −1.74 cm in usual care group (95% CI −2.52, −0.96) (change difference −0.50 cm, 95% CI −1.63, 0.63; group by treatment interaction p = 0.389); and +0.18 mmol/l fasting blood glucose in intervention group (95% CI 0.11, 0.24) compared with +0.22 mmol/l in usual care group (95% CI 0.16, 0.29) (change difference −0.05 mmol/l, 95% CI −0.14, 0.05; group by treatment interaction p = 0.331). Only 10% of women attended all sessions, 53% attended one individual and at least one group session, and 34% attended no sessions. Loss to follow-up was 27% and 21% for the intervention and control groups, respectively, primarily due to subsequent pregnancies. Study limitations include low exposure to the full intervention and glucose metabolism profiles being near normal at baseline. CONCLUSIONS: Although a 1-kg weight difference has the potential to be significant for reducing diabetes risk, the level of engagement during the first postnatal year was low. Further research is needed to improve engagement, including participant involvement in study design; it is potentially more effective to implement annual diabetes screening until women develop prediabetes before offering an intervention. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12610000338066 Public Library of Science 2016-07-26 /pmc/articles/PMC4961439/ /pubmed/27459502 http://dx.doi.org/10.1371/journal.pmed.1002092 Text en © 2016 O’Reilly et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
O’Reilly, Sharleen L.
Dunbar, James A.
Versace, Vincent
Janus, Edward
Best, James D.
Carter, Rob
Oats, Jeremy J. N.
Skinner, Timothy
Ackland, Michael
Phillips, Paddy A.
Ebeling, Peter R.
Reynolds, John
Shih, Sophy T. F.
Hagger, Virginia
Coates, Michael
Wildey, Carol
Mothers after Gestational Diabetes in Australia (MAGDA): A Randomised Controlled Trial of a Postnatal Diabetes Prevention Program
title Mothers after Gestational Diabetes in Australia (MAGDA): A Randomised Controlled Trial of a Postnatal Diabetes Prevention Program
title_full Mothers after Gestational Diabetes in Australia (MAGDA): A Randomised Controlled Trial of a Postnatal Diabetes Prevention Program
title_fullStr Mothers after Gestational Diabetes in Australia (MAGDA): A Randomised Controlled Trial of a Postnatal Diabetes Prevention Program
title_full_unstemmed Mothers after Gestational Diabetes in Australia (MAGDA): A Randomised Controlled Trial of a Postnatal Diabetes Prevention Program
title_short Mothers after Gestational Diabetes in Australia (MAGDA): A Randomised Controlled Trial of a Postnatal Diabetes Prevention Program
title_sort mothers after gestational diabetes in australia (magda): a randomised controlled trial of a postnatal diabetes prevention program
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961439/
https://www.ncbi.nlm.nih.gov/pubmed/27459502
http://dx.doi.org/10.1371/journal.pmed.1002092
work_keys_str_mv AT oreillysharleenl mothersaftergestationaldiabetesinaustraliamagdaarandomisedcontrolledtrialofapostnataldiabetespreventionprogram
AT dunbarjamesa mothersaftergestationaldiabetesinaustraliamagdaarandomisedcontrolledtrialofapostnataldiabetespreventionprogram
AT versacevincent mothersaftergestationaldiabetesinaustraliamagdaarandomisedcontrolledtrialofapostnataldiabetespreventionprogram
AT janusedward mothersaftergestationaldiabetesinaustraliamagdaarandomisedcontrolledtrialofapostnataldiabetespreventionprogram
AT bestjamesd mothersaftergestationaldiabetesinaustraliamagdaarandomisedcontrolledtrialofapostnataldiabetespreventionprogram
AT carterrob mothersaftergestationaldiabetesinaustraliamagdaarandomisedcontrolledtrialofapostnataldiabetespreventionprogram
AT oatsjeremyjn mothersaftergestationaldiabetesinaustraliamagdaarandomisedcontrolledtrialofapostnataldiabetespreventionprogram
AT skinnertimothy mothersaftergestationaldiabetesinaustraliamagdaarandomisedcontrolledtrialofapostnataldiabetespreventionprogram
AT acklandmichael mothersaftergestationaldiabetesinaustraliamagdaarandomisedcontrolledtrialofapostnataldiabetespreventionprogram
AT phillipspaddya mothersaftergestationaldiabetesinaustraliamagdaarandomisedcontrolledtrialofapostnataldiabetespreventionprogram
AT ebelingpeterr mothersaftergestationaldiabetesinaustraliamagdaarandomisedcontrolledtrialofapostnataldiabetespreventionprogram
AT reynoldsjohn mothersaftergestationaldiabetesinaustraliamagdaarandomisedcontrolledtrialofapostnataldiabetespreventionprogram
AT shihsophytf mothersaftergestationaldiabetesinaustraliamagdaarandomisedcontrolledtrialofapostnataldiabetespreventionprogram
AT haggervirginia mothersaftergestationaldiabetesinaustraliamagdaarandomisedcontrolledtrialofapostnataldiabetespreventionprogram
AT coatesmichael mothersaftergestationaldiabetesinaustraliamagdaarandomisedcontrolledtrialofapostnataldiabetespreventionprogram
AT wildeycarol mothersaftergestationaldiabetesinaustraliamagdaarandomisedcontrolledtrialofapostnataldiabetespreventionprogram
AT mothersaftergestationaldiabetesinaustraliamagdaarandomisedcontrolledtrialofapostnataldiabetespreventionprogram